Pliant Therapeutics amends bylaws to align with Delaware law and revise stockholder proposal procedures

PLIANT THERAPEUTICS, INC.

Board approved Third Amended and Restated Bylaws effective September 24, 2024.
Amendments align bylaws with Delaware law developments and include severability provision.
Revised procedural and disclosure requirements for stockholder director nominations and other business proposals.
Changes are ministerial and conforming; no substantive operational or financial impact.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.